MOTS-c vs Humanin
Mitochondrial-Derived Peptide · Mitochondrial-Derived Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
MOTS-c
An endogenous mitochondrial-derived peptide that activates AMPK for metabolic flexibility; functioning as an exercise mimetic in animal models.
Humanin
An endogenous mitochondrial-derived peptide that blocks programmed cell death; first discovered in neurons that survived Alzheimer's neurodegeneration.
MOTS-c
194 studies
19 human trials
Not FDA-Approved
Humanin
255 studies
17 human trials
Not FDA-Approved
What it does
MOTS-c
Activates AMPK, the master metabolic switch, to improve how cells use energy. Functions as an exercise mimetic in animal models, improving glucose uptake and fatty acid oxidation in skeletal muscle. Encoded within mitochondrial DNA and produced naturally by the body, with levels declining with age.
Humanin
Protects cells from programmed death (apoptosis) and oxidative damage, particularly under stress conditions. First discovered in neurons that survived Alzheimer's disease neurodegeneration, suggesting a natural protective role. Encoded within mitochondrial DNA alongside MOTS-c as part of the mitochondrial-derived peptide family.
How it works
MOTS-c
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome (specifically within the 12S rRNA gene), making it one of the first identified mitochondrial-derived peptides. It activates AMP-activated protein kinase (AMPK), the central energy sensor that cells use to respond to low energy states. AMPK activation drives glucose uptake into skeletal muscle, increases fatty acid oxidation, and promotes mitochondrial biogenesis. In animal models, MOTS-c administration mimics some of the metabolic benefits of exercise, improving insulin sensitivity and metabolic flexibility.
Humanin
Humanin is a 21-24 amino acid peptide encoded within the mitochondrial genome (16S rRNA region). It blocks Bax-mediated apoptosis, the process by which stressed or damaged cells self-destruct. By inhibiting Bax, humanin prevents the mitochondrial membrane permeabilization that triggers the cell death cascade. It also reduces oxidative stress and modulates IGF-1 signaling. The cytoprotective effect is most pronounced under stress conditions: humanin appears to protect cells that are under threat of apoptotic death while having minimal effect on healthy cells.
How often
MOTS-c
In published research, MOTS-c has been administered as subcutaneous injection in animal models and a small number of human studies. No FDA-approved product exists. No standardized dosing protocol has been established through regulatory channels.
Humanin
In published research, humanin and its analogs (including HNG, a potent synthetic variant) have been administered in animal models. Human data is limited to observational studies correlating circulating humanin levels with health outcomes. No FDA-approved product exists. No standardized therapeutic dosing protocol has been established.
How strong
MOTS-c
The AMPK-activation mechanism is well-characterized at the cellular level. Animal models show consistent metabolic improvements: enhanced glucose uptake, improved insulin sensitivity, and exercise capacity effects. The endogenous origin (mitochondrial DNA-encoded) provides biological plausibility. Five published human studies document metabolic effects. The age-related decline of endogenous MOTS-c levels is documented, providing the theoretical basis for supplementation research.
Humanin
The cytoprotective mechanism (Bax inhibition) is well-characterized biochemically. Animal models show neuroprotective effects in Alzheimer's models, cardioprotective effects in ischemia models, and metabolic effects in diabetes models. The discovery context (surviving Alzheimer's neurons) provides compelling biological narrative. Circulating humanin levels correlate with health outcomes in human observational studies. However, the gap between mechanistic characterization and therapeutic application remains wide.
Main tradeoff
MOTS-c
Human data is limited to a small number of studies. The exercise-mimetic effects observed in animal models have not been fully replicated in human controlled trials at therapeutic scale. Whether exogenous MOTS-c supplementation can meaningfully rescue the age-related decline in endogenous levels is an open question. Not FDA-approved. The mitochondrial-derived peptide field is relatively new and the long-term effects of supplementation are not characterized.
Humanin
Compelling mechanistic and animal model data with very limited human therapeutic evidence. The Alzheimer's discovery context should not be interpreted as evidence of Alzheimer's treatment efficacy. Exogenous humanin supplementation in humans has not been tested in controlled therapeutic trials. The mitochondrial-derived peptide field is young. Whether supplementation can meaningfully replicate or rescue the endogenous protective function is an open question.
Best for
MOTS-c
- Research on AMPK-mediated metabolic regulation and exercise mimetics
- Research on mitochondrial-derived peptides and their role in aging and metabolic health
- Research comparing mitochondrial-targeted interventions (MOTS-c, SS-31, humanin) across different mechanisms
Humanin
- Research on mitochondrial-derived cytoprotective peptides and Bax-mediated apoptosis inhibition
- Research comparing humanin with other mitochondrial-derived peptides (MOTS-c, SHLP family)
- Research on age-related decline of endogenous protective peptides and the supplementation hypothesis
How to choose
A good fit for MOTS-c
- Research on AMPK-mediated metabolic regulation and exercise mimetics
- Research on mitochondrial-derived peptide signaling in metabolic disease and aging
- Research on endogenous peptides that decline with age and their potential for supplementation
A good fit for Humanin
- Research on cytoprotective mechanisms and Bax-mediated apoptosis inhibition
- Research on mitochondrial-derived peptides in neurodegeneration and cardioprotection
- Research on age-related cell loss and endogenous protective peptide decline
Consider both across time
MOTS-c and humanin are complementary members of the mitochondrial-derived peptide family. MOTS-c addresses the metabolic dimension (how well cells use energy). Humanin addresses the survival dimension (whether stressed cells live or die). Both decline with age. The combination represents two distinct protective mechanisms from the same organellar genome. No controlled combination study has been published.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- AMPK Activation
- AMPK Activation increases Glucose Uptake
- AMPK Activation drives Fatty Acid Oxidation
- AMPK Activation promotes Mitochondrial Biogenesis
- Glucose Uptake connects to Metabolic Flexibility; Fatty Acid Oxidation connects to Metabolic Flexibility
- Mitochondrial Biogenesis connects to Exercise Capacity
- Bax Apoptosis Inhibition
- Bax Apoptosis Inhibition reduces Oxidative Stress Reduction
- Bax Apoptosis Inhibition modulates IGF-1 Signaling Modulation
- Oxidative Stress Reduction connects to Cellular Cytoprotection; IGF-1 Signaling Modulation connects to Cellular Cytoprotection
- Bax Apoptosis Inhibition blocks Apoptosis Resistance
MOTS-c activates AMPK, the master metabolic switch, to improve glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
Humanin blocks Bax-mediated apoptosis, preventing the mitochondrial membrane permeabilization that triggers programmed cell death.
Research Evidence
MOTS-c has five published human studies with quantified metabolic endpoints. Humanin has primarily observational human data (circulating levels correlating with health outcomes) and extensive animal model data across neuroprotection, cardioprotection, and metabolic protection. Neither has a formal clinical trial program. Both have strong mechanistic characterization. The mitochondrial-derived peptide field is relatively new (MOTS-c identified 2015; humanin identified 2001).
- 1.
For metabolic optimization and exercise mimetic effects, MOTS-c has more relevant data.
- 2.
For neuroprotection and cell survival under stress, humanin has the more specific mechanism.
- 3.
For aging research broadly, both represent the frontier of mitochondrial medicine.
- 4.
For available human evidence, MOTS-c is slightly ahead.
Key Limitations
- •No head-to-head comparison.
- •Both are early in clinical development.
- •Humanin's correlational data does not prove causation.
- •The mitochondrial-derived peptide field is young, much is still being discovered.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MOTS-c
"MOTS-c is the longevity peptide everyone should be taking"
Plausible but unproven
"It improves exercise performance and endurance"
Supported by published data
"People are using it as a metabolic reset"
Anecdotal only
Humanin
"Humanin is the anti-Alzheimer's peptide"
Plausible but no human therapeutic data
"High humanin levels are found in centenarians"
Supported by evidence
Safety Comparison
Both are endogenous peptides the body naturally produces, providing biological plausibility for safety. Neither has formal human safety data from controlled interventional trials. The endogenous origin is relevant but does not substitute for clinical safety characterization of exogenous supplementation.
MOTS-c
Limited but favorable. Endogenous peptide. No serious adverse events reported.
Humanin
Limited data. Endogenous peptide. Theoretical safety is favorable.
What the Research Suggests
Both are fascinating signals from an unexpected source, mitochondrial DNA. MOTS-c is further along clinically for metabolic effects. Humanin has broader protective potential but less interventional evidence.